Bayer (OTCPK:BAYRY) (OTCPK:BAYZF) settled +4.4% in Frankfurt trading Thursday as Goldman Sachs upgraded shares to Buy from ...

Goldman Sachs analyst James Quigley upgraded Bayer Aktiengesellschaft (OTC:BAYRY) to Buy from Neutral, while setting a price ...

With inflation running above trend and no imminent threat of recession, Goldman expects yields to remain elevated. The firm ...

Detailed price information for Bayer Aktienges ADR (BAYRY) from The Globe and Mail including charting and trades.

Goldman's president and COO, John Waldron, said the bank is bracing for more volatility as Trump disrupts traditional DC ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Investing.com -- Shares of Bayer AG (ETR: BAYGN) were up over 5% on Thursday after Goldman Sachs upgraded the German pharmaceutical and life sciences company to a "buy" rating from "neutral ...

On Thursday, Goldman Sachs analysts upgraded Bayer AG (ETR:BAYGN) (BAYN:GR) (OTC: BAYRY) stock from Neutral to Buy. The new price target is set at €33.00, up from the previous €29.10.

In a report released today, James Quigley from Goldman Sachs maintained a Hold rating on Bayer (0P6S – Research Report), with a price target of €30.00. The company’s shares closed yesterday ...

Bayer (OTCPK:BAYRY) (OTCPK:BAYZF) settled +4.4% in Frankfurt trading Thursday as Goldman Sachs upgraded shares to Buy from neutral with a €33 price target, raised from €29.10 previously ...